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All patients included in this study met the revised deﬁnition
criteria for fever of unknown origin (FUO): a temperature greater
than 38 8C (101 8F) on several occasions, a duration of illness of
more than 3 weeks, and no identiﬁed diagnosis after adequate
inpatient or outpatient evaluation.1 In clinical practice, we tailored
the published guidelines for clinical cases. Eventually positron
emission tomography/computed tomography (PET/CT) was used
at the discretion of the physician as part of clinical practice. In the
case of normal or misleading results from a series of investigations,
the patient underwent a PET/CT.
The ﬁrst acute myeloid leukemia (AML) patient, whose images
were provided in Figure 1 in the original article,2 was referred from
abroad with long-term non-speciﬁc symptoms including fever,
fatigue, weight loss, shortness of breath, anemia, and non-speciﬁc
skin lesions, which had previously been evaluated by a dermatol-
ogist and evaluated as non-speciﬁc. As seen in the images
provided,2 only some of the lesions were metabolically detectable
and the most hypermetabolic lesion was picked out to guide
biopsy. We experienced a similar clinical scenario with the second
patient with AML (Figure 1A). 18F-Fluorodeoxyglucose (FDG)-PET/
CT was particularly helpful in the early diagnosis of these
challenging patients through monitoring 18F-FDG in the skin
lesions, lymph nodes, and bone marrow. The second patient’s
images was also provided.2http://dx.doi.org/10.1016/j.ijid.2014.06.006
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).PET/CT may be useful for detecting focal localizations in
patients with leukemia. The prevalence of extramedullary disease
(EMD) in AML at the time of diagnosis is unknown and often
remains a diagnostic challenge. Previous estimates range from
2.5% to 30.5% and are usually based on clinical examination. This
may result in an under-diagnosis of EMD, as not all extramedul-
lary manifestations are easily detectable.2 For these patients, we
can consider waiting for a period of time until the skin lesions
worsen and therefore become more easily identiﬁable for
diagnosis. But should we, in the era of advanced diagnostic
technology?
The third patient, who was diagnosed with tuberculosis, had a
complicated clinical history with a severe illness, besides the
FUO. She had pleural effusion, continuous peritoneal dialysis,
and recent weight loss. Standard clinical investigations did not
reveal a deﬁnite diagnosis but raised a strong suspicion that the
patient had a malignancy with an unknown primary source.
Tuberculosis was considered in the differential diagnosis of this
patient; however, several factors that usually occur in immuno-
compromised patients prevented localizing signs of disease.
Despite several CT studies, ﬁndings pathognomonic of tubercu-
losis were not detected. Then, during an exploration of the
malignancy, PET/CT was performed, and the focus was detected
in the mediastinum (Figure 1B). The ﬁnal diagnosis was
established by histological studies.
FUO can be caused by more than 200 infectious, neoplastic,
inﬂammatory, immunological, and other conditions. Because ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. (A) 18F-FDG-PET/CT images of a patient with a histologically established diagnosis of acute myeloid leukemia. (B) 18F-FDG-PET/CT images revealing heterogeneous
FDG activity in the bilateral lungs and increased 18F-FDG uptake in the mediastinal lymph nodes.
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pathology. Imaging techniques such as CT scans and magnetic
resonance imaging (MRI) that concentrate on one area of the
body have limited value if there are no localizing signs or
symptoms.
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